Misplaced Pages

CMV423

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (July 2016)
Pharmaceutical compound
CMV423
Clinical data
Other namesCMV-423; RPR-111423
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 2-Chloro-3-(pyridin-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H14ClN3O
Molar mass275.74 g·mol
3D model (JSmol)
SMILES
  • c1cc(cnc1)c2c(c(c3n2CCCC3)C(=O)N)Cl
InChI
  • InChI=1S/C14H14ClN3O/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17-8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19)
  • Key:KNGXENHWYNLKBU-UHFFFAOYSA-N

CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection and human herpesvirus 6 (HHV-6) infection. The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.

References

  1. Snoeck R, Andrei G, Bodaghi B, Lagneaux L, Daelemans D, de Clercq E, et al. (September 2002). "2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections". Antiviral Research. 55 (3): 413–424. doi:10.1016/s0166-3542(02)00074-8. PMID 12206879.
  2. ^ "CMV 423". AdisInsight. Springer Nature Switzerland AG.
  3. Aoki FY (2015). "45 - Antivirals against Herpes Viruses". In Bennett JE, Blaser MJ, Dolin R (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (8th ed.). pp. 546–562. doi:10.1016/B978-1-4557-4801-3.00045-X. ISBN 978-1-4557-4801-3.
Categories: